Get started
Author

Angus Killean

Observed names: A. Killean, A.J. Killean, Angus J. Killean, Killean, Angus
ORCID: 0000-0003-1463-7793
Observed ORCID: 0000-0003-1463-7793
OpenAlex ID: A5004301409
Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer
2024 · Emma Doyle, Angus J. Killean, et al. · Radiotherapy and Oncology · 17
Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre
2023 · Mark Stares, Georgina Lewis, et al. · Cancers · 9
PDF
Detecting early weight loss in patients with advanced lung cancer
2020 · C. Collinson, A. Killean, et al. · Lung Cancer · 3
Clinical Implementation of Real Time Motion Management for Prostate SBRT: A feasibility study exploring urethral motion, dose and considerations for the Radiation Therapist
2026 · Joanne Mitchell, Duncan B. McLaren, et al. · SSRN Electronic Journal
Clinical implementation of real time motion management for prostate SBRT: A radiation therapist’s perspective
2024 · Joanne Mitchell, Duncan B. McLaren, et al. · Technical Innovations & Patient Support in Radiation Oncology
PDF
Acute Gastrointestinal and Genitourinary Toxicity from Stereotactic Body Radiotherapy for Prostate Cancer following Continuous Tumour Tracking with the Micropos Medical RayPilot and RayPilot HypoCath System®
2023 · A. Killean, J. Mitchell, et al. · Clinical Oncology
PDF
Rates of Neutropenia following the Introduction of G-CSF to Upfront Docetaxel
2023 · A. Swan, A. Killean, et al. · Clinical Oncology
PDF
EP05.01-008 The Scottish Inflammatory Prognostic Score predicts survival in non-small cell lung cancer treated with chemoradiotherapy
2022 · G. Ball, A.J. Killean, et al. · Journal of Thoracic Oncology
PDF
EP02.02-003 Mean Lung Dose Correlates with Volume of Radiation-Induced Lung Injury in Patients Treated with SABR for Lung Cancer
2022 · A.J. Killean, R. Ramaesh, et al. · Journal of Thoracic Oncology
Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?
2022 · James Leach, Mark Stares, et al. · Lung Cancer
Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy
2022 · Benjamin Langley, James Leach, et al. · Lung Cancer
Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy
2022 · Angus Killean, Florence Fenner, et al. · Lung Cancer
Identification of pathogenic EGFR mutation in plasma cell-free DNA by ultra-deep sequencing in a patient undergoing stereotactic ablative radiotherapy (SABR) for early-stage lung cancer
2022 · Angus Killean, John Thomson, et al. · Lung Cancer
Pre-treatment serum albumin is a prognostic biomarker for locally advanced non-small cell lung cancer: extended follow up of patients treated with concurrent chemo-radiotherapy
2021 · Angus Killean, Ashley Horne, et al. · Lung Cancer
Comparing methods of evaluating sarcopenia in stage III/IV lung cancer
2020 · A. Killean, I. Phillips, et al. · Lung Cancer
A deep learning approach for identifying focal prostate cancer from multi-parametric MRI
2019 · Michelle Rooney, Angus Killean, et al. · Physica Medica
EP-1933 A deep learning approach for identifying focal prostate cancer from multi-parametric MRI
2019 · M. RooneY, A. Killean, et al. · Radiotherapy and Oncology
PDF
Evaluating the Safety of Up-front Docetaxel in the Treatment of Metastatic and Locally Advanced Prostate Cancer
2019 · A. Killean, A. Law, et al. · Clinical Oncology
Serum β-hCG in non-small cell lung cancer: a potential marker for early detection and assessing treatment response? A case report
2019 · A. Killean, A. Sundaramurthy, et al. · Lung Cancer
Works count: 20
Citation count: 29
H-index: 3
I10-index: 1
Year
Topic
Type